Description
Focused on lipid control and statin treatment to reduce cardiovascular risk.Program launch date
2019-ongoingResponsible entity
Public healthcare system, partial out-of-pocket for medicationAvailable results and quality metrics
Recognition of high dyslipidemia prevalence; calls for urgent measures to reduce its impact. Less than 30% of treated patients achieved LDL-C targets, contributing to approximately 260,000 annual CVD-related deaths; 67% of patients with dyslipidemia received statins, indicating undertreatment. Low rate of LDL-C control (<30%); moderate statin use (~67%).Limitations / comments
Therapeutic inertia and underdiagnosis; needs better treatment adherence and clinical education. Need for comprehensive national guidelines and increased awareness among healthcare providers.